The Amicus acquisition will bolster BioMarin’s rare disease portfolio, while potentially supporting the company’s revenue ...

Pharmed Foundation and ORD India launched the KK Aurora Light of Hope Fund. The CSR programme will provide free or subsidised ...

Breakthrough research is bringing new hope this Christmas to a Grand Blanc family facing a rare neurological disease.

A powerful profile of Dr. David Fajgenbaum using AI drug repurposing to cure rare diseases and transform medicine.

Combined, the two drugs made revenues of nearly $600 million in the last four quarters, while BioMarin has forecast that its ...

As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

Discover why Mirum Pharmaceuticals, Inc. stock surged 65%. Explore robust pipeline growth, revenue outlook, and analyst ...

Just two months after reviving its prowess in the idiopathic pulmonary fibrosis (IPF) treatment area with rare lung disease ...

However, significant changes have been underway, converging regulatory breakthroughs, maturing AI capabilities, and a broader reconsideration of how therapies are developed and who they serve.

BioMarin Pharmaceutical’s strong rare disease drug portfolio and Amicus acquisition drive a ‘Buy’ rating. Click here to read my latest analysis of BMRN stock.

Past the red carpets and the flashing lights of the paparazzi, some celebrities live in a reality more complicated than what is shown. A number of them live with medical conditions only seen in a tiny ...

Ozempic® can cause gallbladder diseases, including gallstones and gallbladder inflammation. Gallbladder problems are rare — 0 ...